The optimized process uses “proprietary chromatographic columns and processes” and has already been used successfully in the production of mRNA for a candidate COVID-19 vaccine.
“BIA’s expertise in chromatographic columns for mRNA purification combined with BioNet’s expertise in the development of genetic vaccine products have, since early 2021, enabled the two teams to collaborate on optimization and scaling up. in-range of a high throughput mRNA production process. “report companies.
Need for speed: four-month development process
BioNet is a Franco-Thai company specializing in the development, manufacture and supply of genetically modified vaccines; while the Slovenian purification specialist BIA Separations is a developer and manufacturer of Convective Interaction Media (CIM) monolithic chromatographic columns for the production, purification and analysis of large biomolecules such as viruses, plasmids and mRNA ( the company was acquired by Sartorius last year).
It took the companies four months to develop the new process; with coordinated work and technology transfer via teleconferences in the absence of physical meetings and training due to COVID-19 restrictions.
The process has been successfully applied to the production of mRNA for the vaccine candidate ChulaCov19, which was developed by the Chula Vaccine Research Center, Thailand, in collaboration with the University of Pennsylvania, USA (the vaccine was shown to be stimulate the immune system to produce the killer T-cells against alpha, delta, beta and gamma variants of SAS-CoV-2 in a phase 1 study in August; and is expected to move to phase 2/3 trials soon).
BIA and BioNet are now collaborating on other projects aimed at increasing the development and production capacity of nucleic acid vaccines in Europe, Australia and low and middle income countries.